SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
More aggressive, but still treatable form of chronic lymphocytic leukemia. The malignant B cells are larger than average. The name is commonly abbreviated B-PLL. It can involve deletions from chromosome 11 and chromosome 13. It has a relatively poor prognosis.
Malignancy of B-prolymphocytes medium-sized, round lymphoid cells with prominent nucleoli, moderately condensed nuclear chromatin, relatively small amount of faintly basophilic cytoplasm, affecting blood, bone marrow and spleen. Prolymphocytes must exceed 55% of lymphoid cells in blood. Extremely rare, 1% of lymphocytic leukemias.
This neoplasm affects the peripheral blood (PB), bone marrow (BM) and spleen. Prolymphocytes must exceed 55% of lymphoid cells in PB. B-PLL is extremely rare, comprising approximately 1% of lymphocytic leukemias. The leukemic cells are found in the PB, BM and spleen. Patients usually present with massive splenomegaly with absent or minimal peripheral lymphadenopathy and a rapidly rising lymphocyte count.
Definitive Diagnostic Methods
Bone Marrow biopsy
Peripheral blood smear
Ig genes clonally rearranged, t(11;14)(q13;q32) in 20%, abnormalities of p53 in 53%, del at 11q23, del at 13q14